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Abstract
Cerebral malaria (CM) is a lethal neurological complication of malaria. We implemented a genome-wide screen in
mutagenized mice to identify host proteins involved in CM pathogenesis and whose inhibition may be of therapeutic value.
One pedigree (P48) segregated a resistance trait whose CM-protective effect was fully penetrant, mapped to chromosome
8, and identified by genome sequencing as homozygosity for a mis-sense mutation (W81R) in the FERM domain of Janus-
associated kinase 3 (Jak3). The causative effect of Jak3
W81R was verified by complementation testing in Jak3
W81R/2 double
heterozygotes that were fully protected against CM. Jak3
W81R homozygotes showed defects in thymic development with
depletion of CD8
+ T cell, B cell, and NK cell compartments, and defective T cell-dependent production of IFN-c. Adoptive
transfer of normal splenocytes abrogates CM resistance in Jak3
W81R homozygotes, an effect attributed to the CD8
+ T cells.
Jak3
W81R behaves as a dominant negative variant, with significant CM resistance of Jak3
W81R/+ heterozygotes, compared to
CM-susceptible Jak3
+/+ and Jak3
+/2 controls. CM resistance in Jak3
W81R/+ heterozygotes occurs in presence of normal T, B
and NK cell numbers. These findings highlight the pathological role of CD8
+ T cells and Jak3-dependent IFN-c-mediated Th1
responses in CM pathogenesis.
Citation: Bongfen SE, Rodrigue-Gervais I-G, Berghout J, Torre S, Cingolani P, et al. (2012) An N-Ethyl-N-Nitrosourea (ENU)-Induced Dominant Negative Mutation in
the JAK3 Kinase Protects against Cerebral Malaria. PLoS ONE 7(2): e31012. doi:10.1371/journal.pone.0031012
Editor: David R. Beier, Harvard Medical School, United States of America
Received December 2, 2011; Accepted December 29, 2011; Published February 21, 2012
Copyright:  2012 Bongfen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by research grants to PG, MS, SV, MB from the Canadian Institutes of Health Research (CIHR; 216406), to SG, and MAB from
the CIHR, and to ML from the European Union Framework 7 Program READNA (HEALTH-F4-2008-201418). RS is supported by a salary award from the Fonds De
Recherche en Sante ´ du Que ´bec. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: philippe.gros@mcgill.ca
Introduction
Malaria, caused by infection with members of the Plasmodium
family of parasites, still remains a global health problem, with close
to 250 million clinical cases and almost a million deaths occurring
each year, mostly in African children [1]. Cerebral malaria (CM) is
the most severe complication of P. falciparum infection. Although
CM develops in less than 1% of Plasmodium infected individuals, its
sudden onset, rapid progression and limited treatment options
(high dose quinine or artemisnin) contribute to an often-lethal
outcome. CM is characterized by trapping of parasitized
erythrocytes in the host microvasculature including the blood
brain barrier (BBB) that triggers a strong inflammatory response in
situ, vascular damage and hypoxia. Permeability of the BBB leads
to seizures, paralysis, unrousable coma and death [2]. The cell and
molecular pathways involved in CM pathogenesis are poorly
characterized and need to be better understood to identify novel
therapeutic targets for intervention. Clinical epidemiological
studies in different geographical areas of malaria-endemicity have
indicated that the onset, progression and outcome of CM involve a
complex interplay between environmental factors, parasite-ex-
pressed virulence factors and host genetic factors influencing
replication of the parasite or innate or acquired immunity [3,4,5].
Genetic studies in humans have pointed to a heritable component
to susceptibility to CM (reviewed in [6]), while case-control
association studies have suggested a complex and heterogeneous
genetic component in CM, including hemoglobin variants
(hemoglobinopathies), polymorphisms in cytokine genes or gene
promotors, and many others (reviewed by [3,4]).
The complex genetic component of CM susceptibility has also
been investigated in the mouse model for experimental CM caused
by infection with Plasmodium berghei ANKA (PbA). P. berghei
infection in mice closely mimics P. falciparum-induced CM in
humans [7], with susceptible mouse strains (e.g. C57BL/6J, CBA/
J) developing an acute cerebral syndrome within 6–7 days
characterized by ataxia, paraplegia, seizures and coma leading
to uniform lethality by day 8–10 post-infection. Like in humans,
studies in mouse mutants bearing inactivating mutations at specific
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  ,   Maya Salehgenes have shown that host-driven inflammation plays a central
role in CM pathogenesis [2,8]. Indeed, local production of pro-
inflammatory cytokines such as IFN-c [9], TNF-a [10] and LT-a
[11], upregulation of chemokine ligands [12] and cell adhesion
molecules [13], as well as sequestration of immune cells (CD4
+,
CD8
+, NK cells) [12,14,15] and parasites [15] in the brain
microvasculature have all been shown to play a role in CM. On
the other hand, inactivating mutations in genes coding for pro-
inflammatory molecules [16,17], and generation of anti-inflam-
matory cytokines like IL-10 [14] and IL-4 [18] have been
associated with protection from CM.
Genome-wide linkage studies in informative crosses derived from
mouse strains showing varying degrees of susceptibility to P. berghei-
induced CM have detected at least six quantitative trait loci (QTL) -
designated berghei resistance (Berr) loci – as modulating response to
infectionincludingsurvivalfromacuteinfection:Berr1(chromosome
1), Berr2 (chromosome 11), Berr3 (chromosome 9), Berr4 (chromo-
some 4), Berr5 (chromosome 19), and the Cmsc locus mapping to the
H-2 region of chromosome 17 [19,20,21,22]. The Berr5 locus co-
localizes with three other immune loci, including Trl-4 (tuberculosis
resistance), Tsiq2 (T-cell secretion of IL-4), and Eae19 (experimental
allergic encephalitis 19) suggesting the possibility of a common
genetic effect underlying these phenotypes. Nevertheless, the
modest effects of these individual loci, the relatively large size of
the chromosomal regions mapping underneath the QTL peaks, and
the large number of positional candidates have precluded the
positional cloning of the genes involved.
ENU mutagenesis is a powerful experimental tool used to
introduce random mutations in the mouse germ-line. Such
mutations can be propagated in informative pedigrees, where
they can be bred to homozygosity, and where their effect on a
given physiological system or host pathway can be investigated. In
high throughput screening experiments, such mutations may
manifest themselves as rare pheno-deviant pedigrees displaying
unique disease-associated phenotypes. The positional cloning of
the mutant gene, facilitated by the de novo nature of the mutation
(absent from the reference sequence), may in turn identify novel
proteins that play a role in the specific phenotype and associated
pathology. This strategy has been used successfully to identify
genes, proteins and pathways in a broad range of disease states,
including susceptibility to infections [23], obesity [24], muscle
development and function [25], cardiomyopathy [26] and
thrombocytopenia [27].
In this study, we implemented a large scale ENU mutagenesis
strategy to identify genes that play an important role in the
pathogenesis of cerebral malaria. Intravenous infection of C57BL/
6J and C57BL/10J mice with 10
6 P. berghei-parasitized erythro-
cytes is uniformly lethal with all animals developing cerebral
symptoms by day 5–6 and succumbing to infection by days 7–10.
We searched for recessive mutations that would protect mice form
P. berghei-induced CM and associated lethality, and that would
confer survival to this otherwise lethal infection. We aimed to
identify novel protein and biochemical pathways that may
constitute novel targets for small molecule inhibition and
therapeutic intervention in this lethal infection. In a first example
of this screen, we report the identification of a pheno-deviant
pedigree that displays segregation of a CM-resistance phenotype.
We demonstrate that this resistance is phenotypically expressed as
a severe depletion of several immune cell compartments including
CD8
+ T cells, B cells and NK cells, and caused by a mutation in
the Jak3 gene. Resistance to CM in this mutant is associated with
an impaired Th1 response, which is concomitant with increased
susceptibility to infection with mycobacteria (M. tuberculosis), and
Citrobacter.
Results
Identification and characterization of a cerebral malaria
resistant ENU mutant
To identify genes, proteins, and cellular pathways important for
the pathogenesis of cerebral malaria (CM), we screened pedigrees
derived from ENU-mutagenized mice, looking for the appearance
of CM-resistant pheno-deviant pedigrees on the otherwise CM-
susceptible genetic background of C57Bl/6J (B6). Such pedigrees
are believed to segregate protective mutations fixed for homozy-
gosity, and affecting genes that are important for CM pathogenesis
including host-driven detrimental effects. In our protocol,
mutagenized B6 males were crossed to C57Bl/10J (B10, to
facilitate subsequent genetic mapping), and the resulting G1 males
were backcrossed to B10 (Figure 1A); the resulting G2 females (two
per G1 male) were backcrossed to their G1 father to produce G3
pedigrees where mutations are fixed to homozygosity in 25% of
the animals. These G3 pedigrees were infected with P. berghei
ANKA, and we monitored the presence of pheno-deviant progeny
that fail to develop cerebral symptoms and survive this infection.
When such positive pedigrees were detected, additional G3
animals from the same G2 females and G1 father were generated
and phenotyped to validate the presence of a protective mutation.
Screening a total of 3967 G3 mice from 153 pedigrees identified
several such pheno-deviant pedigrees. One of these pedigrees, #48
(P48), displayed a fairly high percentage of resistant animals
(,31% resistance), with both G2 females producing CM-resistant
offspring (Figure 1B), and was chosen for further analysis.
A genome-wide scan was carried out in 44 G3 animals from P48
(15 CM-resistant and 29 CM-susceptible) using 131 polymorphic
markers informative for B6 and B10. Linkage analysis (using R/
qtl) identified a 17 Mb region on the central portion of
chromosome 8 (95% Bayesian credible interval: 60.4 Mb–
77.4 Mb) as regulating differential CM-resistance in this pedigree,
with a logarithm of odds (LOD) score of 5.8 (Figure 2A).
Haplotype analysis revealed that, as expected, resistance to CM at
this locus was associated with homozygosity for B6-derived alleles
(from mutated G0 male), while homozygosity for B10 alleles was
associated with CM-susceptibility, and with B6/B10 heterozygotes
being present in both resistant and susceptible groups (Figure 2B).
These findings suggested that the CM-protective effect of this locus
is co-dominant in this cross. The P48 G1 male was also outcrossed
to CM-susceptible 129S1 WT females, and the resulting offspring
were intercrossed to generate a total of 211 F2 mice, which were
phenotyped by infection with P. berghei ANKA (Figure 2C).
Approximately 25% of these F2 survived the cerebral phase,
indicating that the resistance trait associated with P48 is fully
penetrant on the distinct genetic background of 129S1. Genotyp-
ing of these animals verified that CM resistance was controlled by
the chromosome 8 locus, and also showed a co-dominant mode of
inheritance of B6 protective alleles in this cross (Supplementary
Figure S1).
Immunological phenotyping of P48 mutants
To gain insight into the cell population phenotypically
expressing the CM-protective mutation, we examined different
lymphoid and myeloid organs, and monitored specific cell
populations within them in mice fixed for homozygosity for B6-
derived alleles at the chromosome 8 locus. Macroscopic
examination readily identified severe thymic atrophy in homozy-
gotes (Figure 3A), while heterozygotes were normal, suggesting a
possible thymus development defect. FACS analysis further
identified a severe depletion of the CD8
+ T cell compartment in
thymus of these mice, while the CD4
+ T cell compartment
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+ T cell
compartment was also detected upon analysis of spleen cells from
these mice (Figure 3B), with an additional reduction in NK cells
(Figure 3C). On the other hand, studies of bone marrow cells
showed a complete absence of CD19
+ B cells in mutant mice. In
all tissues examined, there was no effect noted on the myeloid
compartment (Gr1
+ cells). All alterations in these cell populations
were detected only in homozygotes, while heterozygotes showed
normal cell numbers, which were similar to C57BL/6J controls.
Resistance to cerebral malaria is caused by a mutation in
the Jak3 kinase
The 17 Mb interval delineating the position of the CM-
protective locus on chromosome 8 contains a number of positional
candidates that a) have an established role in the immune system,
b) are known to be modulated by IFN-c, or c) show IFN-inducible
STAT1 binding sites in their promoter. These include Interleukin
12 receptor beta 1 (IL12rb1; 73.3 Mb), interferon gamma
inducible protein 30 (Ifi30; 73.2 Mb), Janus kinase 3 (Jak3;
74.2 Mb), heme oxygenase (decycling) 1 (Hmox1; 77.6 Mb) and
unc-13 homolog A (Unc13a; 74.1 Mb). Whole genome sequencing
of genomic DNA from P48 mutant homozygotes was undertaken,
and candidate variants in the above-mentioned genes that were
absent from the B6 reference sequence were further validated by
re-sequencing. This analysis revealed a unique T-to-A transversion
in exon 2 of the Jak3 gene, which causes a W81R substitution in
the Band 4.1/Ezrin/Radixin/Moesin (FERM) homology domain
at the N-terminus of the Jak3 protein (Figure 4). The FERM
domain is involved in mediating interactions of Jak3 with different
cytokine receptors in immune cells. The tryptophan at position 81
is absolutely conserved in Jak3 relatives from different species,
suggesting a conserved structural/functional role of this residue in
Jak3 activity. To confirm that the CM-resistance in P48 mutants
was caused by a mutation in Jak3, we carried out complemen-
tation testing using Jak3
2/2 null mice (B6.129S4-Jak3
tm1Ljb; MGI
database, [28]). These animals have previously been shown to
Figure 1. ENU-induced mutation that protects mice against P. berghei ANKA-induced cerebral malaria. (A) Breeding scheme for the
production and identification of ENU-induced recessive mutations that convey protection against cerebral malaria (CM). Details of the breeding
strategy are described in ‘‘Materials and Methods’’. G3 and F2 pedigrees were phenotyped for the presence of animals resistant to P. berghei-induced
CM. (B) Mice were infected with P. berghei ANKA (10
6 P. berghei ANKA-parasitized red blood cells, i.v.) and survival was monitored over time for
individual pedigree P48 G3s (green and blue lines) derived from independent G2 females and a G1 male, and for susceptible C57BL/6J (B6, red line),
and resistant mutant mouse strains bearing loss of function mutations in either the IFN-c gene KO (IFN-c KO, black line) or IRF8 (BXH2, brown line).
Mice surviving past day 13 post infection were considered to be CM-resistant.
doi:10.1371/journal.pone.0031012.g001
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+
T cells, NK cells and a defect in B cell maturation [28].
Compound (Jak3
W81R/2) heterozygotes were generated by cross-
ing Jak3
W81R homozygotes to Jak3
2/2 null mice, and these
together with Jak3
W81R/+ and Jak3
+/2 heterozygotes were
phenotyped for susceptibility to P. berghei-induced CM. Compound
Jak3
W81R/2 heterozygotes were found to be as CM-resistant as
Jak3
W81R homozygotes and as Jak3
2/2 null animals, confirming
that the Jak3
W81R mutation is indeed responsible for protection
against CM in P48. On the other hand, Jak3
+/2 heterozygotes
were as susceptible to P. berghei induced CM as the B10 WT
controls. Finally, we noted that 50% of Jak3
W81R/+ heterozygotes
were resistant to CM, in agreement with haplotype analyses of the
original G3 animals. This observation together with the uniform
susceptibility of Jak3
+/2 heterozygotes, confirmed the co-domi-
nant mode of inheritance of the Jak3
W81R mutation, and suggested
that it may have a dominant negative effect (Figure 5).
Splenocytes from infected B10 WT mice restore CM
susceptibility to Jak3
W81R homozygous mutant mice
Sequestration of parasitized red blood cells at the brain
microvasculature together with local inflammatory response in
situ, have been shown to be necessary for development and
progression of P. berghei-induced CM [15,29]. We aimed to
establish in cell transfer experiments, which of the immune cell
population(s) missing from the Jak3
W81R mutant mice may be
involved in CM pathogenesis, and which absence results in a CM-
protective effect. First, total splenocytes from normal B10, from
Jak3
W81R/+ heterozygote or from Jak3
W81R homozygote mutants,
harvested 5 days following infection with P. berghei ANKA, were
transferred into Jak3
W81R homozygotes. Two hours later, recipient
and control un-treated mice were infected with P. berghei and the
effect of cell transfer on appearance of CM-associated phenotypes
and lethality were monitored. The transfer of total spleen cells
from wild type B10 controls into Jak3
W81R mutants eliminated
CM-resistance in these animals and they succumbed quickly in the
cerebral phase of the disease, just like un-treated wild type controls
(Figure 6A and 6B). On the other hand, the transfer of total spleen
cells from Jak3
W81R homozygote and, interestingly, from
Jak3
W81R/+ heterozygotes into Jak3
W81R homozygote mutants
had no consequence on the CM-resistance trait of these mice
(Figure 6A and 6B). To determine which of the absent spleen cell
populations is associated with CM-resistance in Jak3
W81R mutants,
we carried out further cell fractionation and transfer experiments
(Figure 6C). While the transfer of NK cells from infected B10 mice
into Jak3
W81R mutants had no effect on CM-resistance, the
transfer of either total T cells or of CD8
+ T cells caused a similar
and significant decrease in survival time following P. berghei
infection of the transferred animals, with 50% of the transferred
mice succumbing by day 9. Together, these results indicate that
CD8
+ T cells are critically important for the pathogenesis of P.
berghei-induced CM, and that their absence in the Jak3
W81R
homozygous mutants is in part responsible for the CM-resistance
phenotype of these mice.
Jak3
W81R mutant mice are susceptible to infection with
Mycobacterium and with Citrobacter
Pro-inflammatory Th1 cytokines (IFN-c, TNF-a and LT-a)
play an important role in CM pathogenesis, and inactivating
mutations in these molecules have a protective effect against P.
berghei-induced CM. Jak3
W81R mutant mice lack CD8
+ splenic T
cells, and total spleen cells from Jak3
W81R mutants do not produce
IFN-c in response to activation along the Th1 pathway (data not
shown). On the other hand, CD4
+ and CD8
+ T cells, as well as
Th1 cytokines produced by these and other cells are absolutely
required for protection against intracellular pathogenic mycobac-
teria [30]. Therefore, we evaluated the response of Jak3
W81R mice
to infection with mycobacteria (Figure 7). Mice were infected with
low dose M. bovis BCG and bacterial replication was measured 6
weeks following infection (Figure 7A). Jak3
W81R mutants showed
splenomegaly and increased spleen bacterial counts (by a factor of
10 fold) compared to control B6 mice. Likewise, a large proportion
(.75%) of Jak3
W81R mutants succumbed within 45 days following
aerosol infection with virulent M. tuberculosis H37Rv, while all of
the control B6 mice survived over the same period (Figure 7B).
Together, these results indicate that inactivation of Jak3 kinase
causes susceptibility to mycobacterial infection. Independently, it is
known that effective protection against enteropathogenic bacteria
such as Citrobacter rodentium requires intact CD4
+ T and B
lymphocyte compartments [31], and is associated with a robust
production of Th1 cytokines such as IFN-c and TNF-a [32,33].
Therefore, we assessed the response of Jak3
W81R homozygote and
Jak3
W81R/+ heterozygote mutants to infection with C. rodentium
(Figure 7C). Inactivation of Jak3 caused a dramatic increase in
susceptibility to infection, leading to progressive mortality within
15 days of infection, compared to B6 and Jak3
W81R/+ heterozy-
gotes which developed transient disease symptoms but survived the
infection. These results indicate that full activation of Jak3 is
required for effective Th1-driven host response to infections with
extracellular and intracellular pathogens.
Discussion
Cerebral malaria has a devastating impact on global health.
The sudden appearance, rapid progression, and irreversible nature
of the CM pathology together with the paucity of treatment
options (limited to high dose parenteral administration of quinine
and artemisinin derivatives [34]), underlie the high rate of
mortality and morbidity associated with CM. Therefore, there is
a desperate need for novel therapeutic interventions. CM has a
complex pathology that involves multiple host tissues and
physiological pathways, including the eyrthroid replicative niche
of the parasite, the structure and secretion products of endothelial
cells of the microvasculature, and different cell populations,
cytokines and associated pathways of the innate and acquired
immune system, the activity of which is triggered by variable
parasite virulence determinants and further modulated by intrinsic
genetic factors of the host [3,4,5]. A better characterization of the
molecular pathways involved is required to identify novel targets
Figure 2. Resistance to cerebral malaria in pedigree 48 maps to the central portion of chromosome 8. Genome-wide linkage analysis of
the CM-resistance trait (survival) was conducted in 44 G3 (15 resistant, 29 susceptible) mice from pedigree 48, using polymorphic markers informative
for the B6 and B10 progenitors. (A) LOD score traces identifying significant linkage to chromosome 8 (p=0.05, genome-wide significance shown as
dotted line); the position of informative markers is shown, including rs33080067 and rs32729089 (LOD score ,5.8). (B) Haplotype analysis of the
central portion of chromosome 8 in CM-resistant and CM-susceptible G3 animals from pedigree 48 (A, B6 homozygotes; H, B6/B10 heterozygotes; B,
B10 homozygotes) showing exclusion of homozygote B6 haplotypes from the CM-susceptible group. The positions of the markers (in Mb) from the
centromere (shown as a grey dot) are shown. (C) The G1 male from pedigree 48 was out-crossed to 129S1/SvlmJ to generate an F2 population
(n=211) that was phenotyped for response to P. berghei ANKA infection. Survival of F2 mice as well as parental 129S1/SvlmJ and C57BL/10J controls
is shown.
doi:10.1371/journal.pone.0031012.g002
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31012Figure 3. Phenotypic expression of resistance to cerebral malaria in mice from pedigree 48. G3 and F2 mice homozygote (P48/P48) or
heterozygote (P48/+) for the B6-derived mutant central chromosome 8 were identified by genotyping, and were subjected to several analyses, along
with parental C57BL/6J, C57BL/10J and 129S1/SvlmJ controls. (A) Macroscopic examination of thymus from control and mutants showing severely
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in human clinical cases of CM and experiments in mouse models
of P. berghei-induced CM have identified excessive TNF-a and IFN-
g-driven inflammatory response as a key determinant in CM
pathogenesis [2]; novel strategies to blunt this response have
shown promise in the prevention and treatment of CM
[35,36,37,38,39]. We have implemented a genome-wide muta-
genesis screen in mice to systematically identify genes and proteins
that mediate pathological inflammatory responses during P. berghei
infection in vivo, and whose pharmacological or genetic inactiva-
tion may protect from CM.
We report on the first mutant identified in this screen. Linkage
analyses, genomic DNA sequencing, and complementation studies
in double heterozygotes have established that CM protection in
this mutant is caused by a mutation (W81R) in the amino-terminal
FERM domain of Jak3 (Janus kinase 3; Jak3
W81R). Jak3 is a
cytosolic tyrosine kinase expressed primarily in the hematopoietic
system that plays a critical role in: a) the ontogeny of different
myeloid and lymphoid cells, and b) the response of these cells to
stimulation by different cytokines. Jak3 interacts with the common
gc chain of type 1 and 2 cytokine receptors, which includes IL-2,
IL-4, IL-7, IL-9, IL-15 and IL-21. This interaction causes
recruitment and phosphorylation of STAT family members to
trigger downstream transcriptional responses in cells expressing
such receptors [40]. In humans, loss of either JAK3 or IL2RG
(which codes for the common gc chain) causes autosomal and X-
linked T
2B
+ SCID, respectively [41]. These patients lack T cells
and NK cells, have normal numbers of immature and poorly
functional B-lymphocytes, a clinical picture in agreement with the
established roles of IL-7 (T cell development), IL-2 (peripheral T
cell homeostasis and antigen-driven T-cell expansion), IL-15
(differentiation of NK cells), and IL-4 (B-cell maturation and
isotype switching) in which associated signaling is impaired in
JAK3 mutants [41]. Jak3
W81R homozygote mice showed a
phenotype that overlaps T
2B
+ SCID in humans, and displayed
an atrophied thymus, a low number of thymic and splenic CD8
+ T
cells and NK cells, as well as a near absence of B cells in the bone
marrow. CD4
+ T cells were present in normal numbers but
appeared anergic and did not produce IFN-g in response to
simulation with PMA or ionomycin (under conditions of Th1
atrophied thymus in homozygote mutants (representative of 5 mice per group). (B) FACS density plots of different cell populations in thymus (top),
spleen (middle) and bone marrow (bottom) stained for CD4, CD8, CD19, and CD117. The position of the different cell lineages in the scatter plots are
identified at the extreme right panel and their numbers are expressed as a percentage (6 SE; n=5 mice per group) of total cells in this tissue. (C) Flow
cytometric analysis of immune cell lineage composition expressed as the absolute number (mean 6 SD; n=4–6 mice per group) of CD4
+ and CD8
+
single positive (SP), CD4
+CD8
+ double positive (DP), B cells (CD19
+), granulocytes (GR; Gr1
+), hematopoietic stem cells (HSC; lineage
2CD117
+) and NK
cells from 10
5 cells from spleen, thymus and bone marrow. Asterisks (one-way Anova test with Bonferroni post-test) identify significant differences
between experimental animals and the C57BL/6J controls: *p,0.05; ** p,0.01; *** p,0.001. Data are representative of two independent
experiments.
doi:10.1371/journal.pone.0031012.g003
Figure 4. A W81R mutation in the FERM domain of Jak3 causes resistance to cerebral malaria in pedigree 48. (A) Schematic
representation of the Jak3 protein, showing the 7 Jak Homology (JH) structural domains, and associated functional annotation (below). The position
of the W81R mis-sense mutation discovered in pedigree 48 is shown. (B) Multiple sequence alignment of the amino terminal portion of Jak3
surrounding W81 shows high conservation across Jak3 relatives (the corresponding species is identified).
doi:10.1371/journal.pone.0031012.g004
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resembled that of previously described Jak3 knockout mice [28].
What is the mechanism underlying protection against P. berghei-
induced CM in Jak3
W81R homozygotes? IFN-g plays a critical role
in initiating and amplifying pathological inflammatory response
during CM, and mouse mutants lacking the IFN-g gene are
protected against P. berghei-induced CM (Fig. 1B, [42,43]).
Although the dominant cell type(s) responsible for early production
of IFN-g in vivo during P. berghei infection has been debated, NK
cells, CD4
+ and CD8
+ T cells have all been implicated [44,45],
and all three populations are affected in Jak3
W81R homozygotes. In
the case of NK cells, results either supporting or excluding a role
for these cells in CM pathogenesis have been published. In one
study, depletion of NK cells failed to alter the appearance of
cerebral symptoms or the outcome of CM in P. berghei infected
mice [43], while another study found that IFN-g secretion by NK
cells was important for recruitment of CXCR3
+ CD4
+ and CD8
+
T cells to the brain and development of cerebral disease [43,44].
On the other hand, cell depletion and cell transfer experiments in
vivo have shown that IFN-g production by CD4
+ and CD8
+ T cells
can both contribute to CM pathogenesis [12,46,47,48]. Results
from our adoptive transfer studies in Jak3
W81R homozygotes
(Figure 6) provide additional insight into this question. We
observed that: a) total spleen cells from C57BL/10J mice were
the only cell population that could fully restore CM-susceptibility
in the mutants; b) total T cells and purified CD8
+ T cells had a
similar effect and caused partial but significant reversion to CM
susceptibility in Jak3
W81R animals; c) transfer of purified wild type
NK cells had no impact on the CM resistance of the Jak3
W81R
mutants. These results strongly suggest that CD8
+ T cells are the
major cell type contributing to CM pathogenesis, although other
spleen cell populations or other cell:cell interactions, for example
T cell dependent NK cell activation [49], appear to be required to
observe the full effect. Nevertheless, our results clearly establish a
role of the Jak3 kinase in the pathogenesis of cerebral malaria.
This participation may reflect the function of Jak3 in the ontogeny
of cell populations (NK cells, CD8
+ T cells) that produce IFN-g
and other soluble mediators of the pathological inflammatory
response that are absent in the Jak3
W81R mutant. The protective
effect of Jak3
W81R may additionally involve inhibition of gc chain-
dependent cytokine receptor signaling in other cell types, whose
ontogeny is not affected by the Jak3 mutation. Nevertheless, our
results suggest that pharmacological inhibition of Jak3 may be of
therapeutic value in CM. Several small molecule Jak3 inhibitors
have been developed and are undergoing clinical evaluation for
inflammatory conditions such as rheumatoid arthritis, psoriasis
and several autoimmune conditions including autoimmune
encephalitis, and rejection of organ transplants [50,51]. Our
findings raise the interesting possibility that Jak3 inhibition by
some of these molecules may represent a novel strategy for
intervention in clinical cases of CM, a proposition that can be
tested experimentally.
An intriguing finding of our study is the intermediate CM-
resistance phenotype characteristic of Jak3
W81R/+ heterozygotes,
with a proportion of these animals either succumbing late in the
cerebral phase or completely surviving the cerebral phase. This
was first noticed in haplotype analyses of G3 mice of pedigree 48,
with animals heterozygote for the chromosome 8 markers being
found in both the CM-resistant and CM-susceptible groups
(Figure 2B), and subsequently verified during P. berghei infection
of genotyped Jak3
W81R/+ hetrozygotes (Figure 5). The effect is not
caused by the genetic background of the animals and is specific for
Jak3
W81R/+ heterozygosity, as is seen when the mutation is
introduced onto either B6/B10 or B6/B10-129S1 mixed genetic
backgrounds (Figures 2B, S1). The cellular and molecular basis of
co-dominance of the Jak3
W81R mutation is intriguing. It could be
explained either by a partial loss of Jak3 function in a dosage
dependent pathway or by a specific dominant negative effect of the
Jak3
W81R allele. The observation that mice heterozygote for a null
Jak3 mutation (Jak3
+/2) are as susceptible to CM as wild type B6
controls clearly argues for the latter possibility. Interestingly,
immunophenotyping results of Jak3
W81R/+ heterozygotes show
that CM protection in these animals is not associated with
alterations in the numbers of NK, T and B lymphocytes, which are
all present at normal levels when compared to controls (Figures 3B,
3C). Normal production of IFN-g in response to PMA and
ionomycin stimulation under Th1 polarization assay conditions is
also seen in Jak3
W81R/+ heterozygotes (data not shown). This
suggests the possibility of a more subtle dominant negative effect of
Jak3
W81R on the biochemical properties of Jak3 in cytokine
signaling, and that would nevertheless be critical for establishing
the inflammatory process during CM. Such a mechanism could
take place in the context of sufficient Jak3 activity that would a)
allow seemingly normal maturation of different immune cell
lineages (NK, B, T cells), but b) not be sufficient to mediate
appropriate signaling during an acute inflammatory situation such
as CM. The inability of transferred Jak3
W81R/+ heterozygote
spleen cells to modify CM-resistance of Jak3
W81R homozygotes
Figure 5. Resistance to cerebral malaria in Jak3
W81R/2 com-
pound heterozygotes. Jak3
W81R homozygotes were crossed to a
mouse line bearing a null Jak3 allele (Jak3
2/2) to create the Jak3
W81R/+
compound heterozygotes. Single heterozygotes (Jak3
W81R/+, Jak3
+/2;
Fig. 5A), homozygotes (Jak3
W81R, Jak3
2/2;F i g .5 B ) ,c o m p o u n d
heterozygotes (Jak3
W81R/2, gray line; Fig. 5A) and C57BL/10J controls
were infected with 10
6 P. berghei ANKA-parasitized RBCs and monitored
for survival. All surviving mice were sacrificed on day 15 post-infection
(experimental end-point). The data are representative of 2 independent
experiments.
doi:10.1371/journal.pone.0031012.g005
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Jak3
W81R/+ heterozygotes being linked to an intrinsic cell
autonomous defect of Jak3
W81R/+ T/B/NK cells which are
present in normal numbers in these mice. Finally, a similar
scenario has been previously proposed to account for incomplete
penetrance and/or partial expressivity of the human SCID
phenotype caused by homozygosity for loss of function JAK3
mutations in certain familial cases [52].
What would be the molecular basis of a dominant-negative
effect of W81R on Jak3 function? Ligand-induced oligomerization
of cytokine receptors and associated Jak3 kinases may position wild
type and mutant Jak3 variants in close proximity in a signaling
complex. In this context, inter-molecular dominant negative
effects of gain-of-function Jak3 alleles such as W81R may alter
the function of the wild type protein expressed in the same cell.
W81 maps in the amino-terminal FERM domain, and several
FERM domain mutations have been reported in SCID patients,
including M1V, A58P, Del58A, 203DelG, Y100C, D169E and
P151R [41,53,54]. The study of these and other site-directed
FERM domain mutants indicate that this domain plays a key role
in multiple aspects of Jak3 function ([54], reviewed in [55]). It is
required for membrane targeting and for interaction with the gc
chain of cytokine receptor [54,56]. It also acts as a positive
regulator of Jak3 kinase activity: it physically interacts with the
JH1-JH2 kinase domain to stimulate both ATP binding and
tyrosine phosphorylation [54]. Such interactions may be critical in
the early cross-phosphorylation of Jak kinases that normally
precedes phosphorylation of neighboring substrates [57]. A
Figure 6. Cell transfer experiments to induce susceptibility to cerebral malaria in Jak3
W81R mice. Wild type C57BL/10J (B10) mice,
Jak3
W81R homozygote mutants (Fig. 6A), or Jak3
W81R homozygote mutants having received the indicated cell populations (20 million total splenocytes
or 5 million each of the indicated cell population; 2 hrs prior to infection); (Fig. 6A, 6B, 6C) were infected i.v. with 10
6 P. berghei ANKA-parasitized
RBCs, and survival from infection was monitored. Untreated wild type B10 and Jak3
W81R mutants were used as susceptible and resistant controls,
respectively. All surviving mice were sacrificed on day 15 post-infection (experimental end-point). Data represent 2 independent experiments.
doi:10.1371/journal.pone.0031012.g006
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inhibition of these early cross-phosphorylation events in heterodi-
mers containing both wild type and mutant variants. Jak3 kinase
activity is modulated by interaction with several proteins including
JAB (Jak binding proteins), CIS, SOCS, SSI, STAM, PIAS and
others [41,58]. A dominant negative effect of W81R may involve
stabilization of an inhibited state following interaction of wild type
and or mutant variants with these modulators. Additional
biochemical studies will be required to elucidate the molecular
mechanism of the W81R dominant negative effect.
Finally, although the full blown T
2/B
+ SCID disease is caused
by complete loss of JAK3 function in humans (homozygosity or
Figure 7. The Jak3
W81R mutation confers susceptibility to infection with different bacterial pathogens. (A) Control (C57BL/6J) and
Jak3
W81R homozygote mutants were infected with 5610
4 colony-forming units (CFUs) of Mycobacterium bovis (BCG), and 6 weeks later, mice were
sacrificed and the degree of infection was assessed by determination of spleen CFUs (left) and splenomegaly (spleen index; right). (B) Jak3
W81R
homozygotes and B6 controls were infected by aerosol inoculation of 50 CFUs/lung of Mycobacterium tuberculosis H37Rv, and monitored for survival.
(C) Jak3
W81R homozygotes, Jak3
W81R/+ heterozygotes and B6 controls were infected by oral gavage with 3610
8 CFUs of Citrobacter rodentium strain
DBS100. Mice were monitored for survival for 30 days post infection. Data represent two independent experiments.
doi:10.1371/journal.pone.0031012.g007
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the mouse Jak3
W81R allele suggest that heterozygosity for
dominant negative human JAK3 mutations may cause partially
impaired immune response. Although immunodeficiency associ-
ated with heterozygosity for a JAK3 mutation has rarely been
reported (most of the JAK3 mutations identified to date are
homozygous or compound heterozygous)[45,57], our findings
raise the possibility that a spectrum of mild immunodeficiency
associated with heterozygote JAK3 mutations may be broader than
previously suspected.
Materials and Methods
Ethics statement
All mice were maintained under pathogen-free conditions and
handled according to the guidelines of the Canadian Council of
Animal Care. The experimental protocol (Protocol number 5287)
was approved by the ethics committee of McGill University.
Mice and parasites
Wild type (WT) C57BL/6J (B6), C57BL/10J (B10) and 129S1/
SvImJ (129S1) mice were purchased from the Jackson laboratories
(Bar Harbor, Maine, USA). ENU-mutagenized mice were bred at
the animal facility of the Goodman Cancer Centre, McGill
University. Mice were maintained under pathogen-free conditions
and handled according to guidelines of the Canadian Council on
Animal Care. P. berghei ANKA parasites were a kind gift from Dr.
Mary M. Stevenson, Montreal General Hospital Research
Institute, McGill University. Parasites were maintained as frozen
stocks at 280uC, and passaged weekly in B10 mice (donor mice).
Infected B10 mice were monitored daily for parasitemia and when
parasitemia reached 4–7%, mice were bled, and the blood was
diluted in 16 phosphate-buffered saline (PBS) for infection of
ENU-mutagenized mice.
ENU Mutagenesis and breeding
Twenty 8-week-old WT B6 male mice were mutagenized by
intraperitoneal injection of a fractionated dose of 3690 mg/kg of
ENU at 1-week intervals. After recovery of fertility (8–15 weeks
post treatment), treated males were used in a breeding scheme
designed to uncover recessive mutations as previously described
[59]. Briefly, treated males (G0) were bred to WT B10 females to
generate G1 animals, which are heterozygous for mutations across
their genome. G1 males were crossed to B10 females to generate
G2 animals, each of which has a 50% chance of inheriting any
single mutation carried by their G1 father. Two G2 females were
backcrossed to their G1 father to generate G3 animals, about a
quarter of which were expected to be homozygous for mutations
carried by the G1 male. In order to introduce a higher degree of
polymorphism in the offspring to facilitate genetic mapping, G1
males from pedigrees with a confirmed heritable resistance trait
(after phenotyping of G3 animals) were out-crossed to 129S1
female mice to generate F1 animals. F1 mice were intercrossed to
generate F2 animals, 25% of which were expected to carry the
mutation from the G1 male fixed to homozygosity (Figure 1A).
Infection with Plasmodium berghei ANKA
G3 and F2 mice at $7 weeks of age were infected intravenously
(i.v.) with 10
6 P. berghei ANKA-parasitized erythrocytes (obtained
from parasite donor mice), and were monitored 2–3 times daily for
the appearance of characteristic neurological symptoms, for
weight loss and for survival. Mice that survived greater than 13
days post infection with no neurological symptoms were
considered to be resistant to cerebral malaria. B10 and 129S1
mice were used as susceptible controls in all experiments, while
IFN-c knockout (KO) mice (on a B6 background) were used as
resistant controls.
DNA preparation and Genetic Mapping
Tail biopsies were obtained from all mice, and genomic DNA
was isolated by a standard procedure using proteinase K digestion
and phenol/chloroform extraction, as previously described [60],
and DNA samples were diluted to 20 ng/ml in distilled H2O for
genotyping. Genome scanning was performed at the McGill
University and Genome Quebec Innovation Centre (Montreal,
Qc, Canada), using DNA samples from 15 resistant and 29
susceptible G3 mice from pedigree 48 (P48), and the massArray
platform from Sequenom with a panel of 131 B6/B10 polymor-
phic markers (SNPs) distributed across the genome. Mapping data
were analyzed with the R/qtl software version 2.10.1. The binary
model was used, and LOD scores calculated using survival as a
phenotype. The cutoff for genome-wide significance (p,0.05) was
3.23. Further linkage analysis was conducted in 211 additional
(P48 X 129S1) F2 mice (see Figure 1A) genotyped for
microsatellite markers (Mouse Genome Informatics Database;
www.informatics.jax.org) informative for B6 and 129S1 progen-
itors. Genotyping was carried out by a standard PCR-based
method using [a-
32P] dATP labeling, and resolution on denaturing
6% polyacrylamide gels.
Genome Sequencing and analysis
The genome of the P48 mutant homozygotes was sequenced
using whole-genome shotgun sequencing with 8 lanes of the
Illumina GAII sequencer, yielding 133 million 76bp reads (9.1
Gbases in total, corresponding to a 36coverage of the genome).
Sequence extraction and base calling was done using Illumina
Pipeline software. Reads were trimmed at five base running
median quality value Q=20 and aligned to the reference genome
(mm37) using Bowtie (PMID: 19261174) and BWA (PMID:
19451168). Variant calling was performed using SamTools
(PMID: 19505943) and results from both mapping methods were
merged after variant calling, producing a total of 350,607
candidate variants. After filtering out non-homozygous and low
coverage SNPs (less than 36) and retaining only coding non-
synonymous/non-sense mutations using the ENSEMBL’s variant
effect predictor, this number was reduced to only 831 variant
candidates. Only 6 of those were located in the 17 Mb region of
chromosome 8 to which the mutation had been mapped, including
2 candidate mutations in the Jak3 gene.
Immunophenotyping
Following isolation of cells from different tissues (spleen, thymus,
bone marrow, lymph nodes and blood), the cells were surface
stained with appropriate dilutions of antibodies (determined from
titration experiments), for 20 minutes in the dark at 4uC, fixed in
PBS containing 1% formaldehyde and stored at 4uC in the dark
until FACS analysis (performed within 24 h). The following anti-
mouse monoclonal antibodies were used: FITC anti-CD4 (RM4-
5), PE anti-CD8a (53-6.7), PECy7 anti-CD19 (1D3), APC anti-
CD11c (HL3), APCCy7 anti-GR1 (RB6-8C5), V450 anti-CD117
(2B8) (all from BD Pharmingen); PerCPCy5.5 anti-F4/80 (BM8),
PerCPCy5.5 anti-CD3e (145-2C11) and eFluor 450 anti-CD11b
(MJ7/18) (all from eBioscience). A minimum of 10
5 cells was
collected by FACS for each tissue sample. Data analysis was
performed using FACS DiVa version 6.0 software. Initial gating of
each sample set used a forward scatter (FSC)-area versus an FSC-
height plot to gate out cell aggregates. Immune cells were isolated,
and the different cell populations stained with various antibodies
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by flow cytometry.
Adoptive transfer experiments
Adoptive transfer was carried out as previously described [12].
Briefly, 8- to-10-week-old wild type (C57BL/10J; B10) or P48
homozygous mutant (P48/P48) mice were injected i.v. with 10
6 P.
berghei ANKA-parasitized erythrocytes (RBC). Five days later,
spleens were collected in RPMI-3% FBS, and single cell
suspensions of viable cells were prepared. Cells were washed in
RPMI-3% FBS by centrifugation, and RBC were lysed by re-
suspending the final pellet in red blood cell lysis buffer (Sigma),
and incubating for 1 minute at RT. Cells were washed again twice
as before and counted. CD8
+ T cells, total T cells or NK cells were
purified from infected B10 WT splenocytes by magnetic cell
sorting (MACS; Miltenyi) according to the manufacturer’s
instructions. 5 million CD8
+ T cells, total T cells or NK cells
from B10 WT infected spleens, or 20 million total WT or mutant
splenocytes were transferred i.v. into P48/P48 mutant animals.
Two hours later, control and reconstituted mice were infected with
10
6 P. berghei ANKA parasites and were monitored for appearance
of cerebral symptoms and for overall survival.
Infection with Mycobacterium bovis (BCG) and
Mycobacterium tuberculosis
Single cell suspensions of Mycobacterium bovis BCG (strain
Montreal) was prepared for in vivo infections as previously
described [61]. Briefly, 5610
4 colony-forming units (CFUs) were
inoculated intravenously into 8–12 week-old mice. Six weeks after
infection, mice were sacrificed, weighed and the spleen CFUs were
determined by homogenization and plating on Dubos oleic agar
base. The level of BCG infection was defined as the logarithm of
the mean number of viable BCG recovered from spleens. The
spleen index was defined as the square root of the spleen weight
(6100) divided by the body weight. For Mycobacterium tuberculosis
(Mtb) infection, 8–12 week-old mice were infected with 50 CFUs/
lung of M. tuberculosis H37Rv by the aerosol route, and survival
was monitored.
Infection with Citrobacter rodentium
Mice were infected at four weeks of age with Citrobacter rodentium
strain DBS100. C. rodentium was grown overnight in 3mL Luria-
Bertani (LB) broth shaking at 37uC. Mice were infected by oral
gavage of 0.1 mL of the overnight culture containing 3610
8
CFUs. Following infection with C. rodentium, the mice were
monitored daily for 30 days post-infection. When any mouse
became moribund or reached a clinical endpoint of infection (20%
body weight loss, hunching and shaking, inactivity, ruffled fur,
anal prolapse, overtly bloody stool, bleeding from the anus and
body condition score ,2), it was immediately euthanized.
Supporting Information
Figure S1 Haplotype map of F2 mice from pedigree 48
for the central portion of chromosome 8 (51.9–84 Mb).
F2 mice generated by crossing the G1 male to 129S1 progenitors
were genotyped for microsatellite markers (Mouse Genome
Informatics Database; www.informatics.jax.org) in the 51.9–
84 Mb interval, and were phenotyped for resistance and
susceptibility to P. berghei induced CM. Each row represents the
haplotype (A, homozygote B6; H, heterozygote; B, homozygote
129S1) of an individual mouse for the indicated polymorphic
markers.
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